Genomisk medicin som forbrugervare

Publikation: Bidrag til tidsskrift › Tidsskriftartikel › Forskning › fagfællebedømt

Standard

Genomisk medicin som forbrugervare. / Folkersen, Lasse; Werge, Thomas.

I: Ugeskrift for Laeger, Bind 181, V11180789, 2019.

Publikation: Bidrag til tidsskrift › Tidsskriftartikel › Forskning › fagfællebedømt

Harvard

Folkersen, L & Werge, T 2019, 'Genomisk medicin som forbrugervare', Ugeskrift for Laeger, bind 181, V11180789. <https://ugeskriftet.dk/videnskab/genomisk-medicin-som-forbrugervare>

APA

Folkersen, L., & Werge, T. (2019). Genomisk medicin som forbrugervare. Ugeskrift for Laeger, 181, [V11180789]. https://ugeskriftet.dk/videnskab/genomisk-medicin-som-forbrugervare

Vancouver

Folkersen L, Werge T. Genomisk medicin som forbrugervare. Ugeskrift for Laeger. 2019;181. V11180789.

Author

Folkersen, Lasse ; Werge, Thomas. / Genomisk medicin som forbrugervare. I: Ugeskrift for Laeger. 2019 ; Bind 181.

Bibtex

@article{8011bf00a88d4733b9d5ce31c6e1ec41,
title = "Genomisk medicin som forbrugervare",
abstract = "In this review, current trends in personal genetics are covered. The main differences between the {"}classic{"} rare high-effect mutations vs the combined effects of thousands of common, low-risk variants are outlined, and then we provide examples of possible clinical use of microarray-based genetic measurements of rare high-risk mutations, and diagnosis-specific polygenic risk scores. The aim of this review is to discuss the possible clinical relevance vs the hyped and potentially harmful overinterpretations of direct-to-consumer genetics services.",
keywords = "Community Participation, Genetic Testing, Genomics, Humans, Medicine, Precision Medicine",
author = "Lasse Folkersen and Thomas Werge",
year = "2019",
language = "Dansk",
volume = "181",
journal = "Ugeskrift for Laeger",
issn = "0041-5782",
publisher = "Almindelige Danske Laegeforening",

}

RIS

TY - JOUR

T1 - Genomisk medicin som forbrugervare

AU - Folkersen, Lasse

AU - Werge, Thomas

PY - 2019

Y1 - 2019

N2 - In this review, current trends in personal genetics are covered. The main differences between the "classic" rare high-effect mutations vs the combined effects of thousands of common, low-risk variants are outlined, and then we provide examples of possible clinical use of microarray-based genetic measurements of rare high-risk mutations, and diagnosis-specific polygenic risk scores. The aim of this review is to discuss the possible clinical relevance vs the hyped and potentially harmful overinterpretations of direct-to-consumer genetics services.

AB - In this review, current trends in personal genetics are covered. The main differences between the "classic" rare high-effect mutations vs the combined effects of thousands of common, low-risk variants are outlined, and then we provide examples of possible clinical use of microarray-based genetic measurements of rare high-risk mutations, and diagnosis-specific polygenic risk scores. The aim of this review is to discuss the possible clinical relevance vs the hyped and potentially harmful overinterpretations of direct-to-consumer genetics services.

KW - Community Participation

KW - Genetic Testing

KW - Genomics

KW - Humans

KW - Medicine

KW - Precision Medicine

M3 - Tidsskriftartikel

C2 - 30950382

VL - 181

JO - Ugeskrift for Laeger

JF - Ugeskrift for Laeger

SN - 0041-5782

M1 - V11180789

ER -

ID: 241225840